Ignite Creation Date:
2025-12-24 @ 2:48 PM
Ignite Modification Date:
2026-02-23 @ 11:34 AM
Study NCT ID:
NCT04338659
Status:
COMPLETED
Last Update Posted:
2023-10-10
First Post:
2020-03-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-01-14
Start Date Type:
ACTUAL
Primary Completion Date:
2023-02-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-02-28
Completion Date Type:
ACTUAL
First Submit Date:
2020-03-24
First Submit QC Date:
None
Study First Post Date:
2020-04-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-06
Last Update Post Date:
2023-10-10
Last Update Post Date Type:
ACTUAL